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Abstract
Background: Proton pump inhibitors (PPIs) are used for the treat-
ment and prophylaxis of variety of acid peptic conditions includ-
ing stress ulcers. There has been a persistent practice of their in-
appropriate use for stress ulcer prophylaxis. Purpose of our study 
was to measure the inappropriate use of Intravenous Proton Pump 
Inhibitors for stress ulcer prophylaxis and to estimate the financial 
burden. 
Methods: We carried out a retrospective, analytic study from July 
2008 to June 2009 in internal medicine department. Hospital phar-
macy records were used to identify all patients who received IV PPI 
during hospital stay. Seventy-five percent of records were randomly 
chosen (n = 1104). PPI application was defined as indicated accord-
ing to AGA guidelines
Results:  Intravenous  proton  pump  inhibitor  (IV  PPI)  was  pre-
scribed for 68.5% of patients without any proper indication. The 
estimated cost of medication for inappropriate IV PPIS use during 
the study year was 18337 USD.
Conclusions: A more rational use of PPI will have better impact on 
health care cost and is likely to add to patient safety.
Keywords:  Inappropriate  use  of  PPI;  Stress  ulcer  prophylaxis; 
Healthcare cost
Introduction
Proton pump inhibitors (PPIs) are widely used for the treat-
ment and prophylaxis of acid peptic conditions including 
stress ulcers [1].
Stress ulceration is a form of hemorrhagic gastritis that 
may  occur  following  trauma  or  critical  illness.  Since  the 
first PPI omeprazole was introduced in 1989, other drugs in 
the class have been marketed: esomeprazole, lansoprazole, 
pantoprazole  and  rabeprazole. There  has  been  a  substan-
tial, continuing and unexplained rise in prescribing of PPIs. 
Approximately 20.5 million prescriptions were written for 
omeprazole in 2007. In 2007, sales of PPIs in the United 
States accounted for about 10 billion dollars. PPIs are there-
fore amongst the most abuse and misused drugs in medicine. 
There is growing evidence regarding safety profile and side 
effects of these medications [2]. Purpose of our study was to 
measure the inappropriate use of intravenous proton pump 
inhibitors (IV PPIs) for stress ulcer prophylaxis (SUP) in pa-
tients admitted to hospital (floor and ICU) and to estimate 
the financial burden.
 
Patients and Methods
We carried out a retrospective, analytical study from July 
2008 to June 2009 in our Medicine department. Written in-
formed consent was not needed, as study was based on chart 
reviews only. Approval was obtained from the hospital Insti-
tutional Review Board before initiation of the study. Hospi-
tal pharmacy records were used to identify all patients who 
received IV PPIs during hospital stay. Esomeprazole is used 
as formulary PPI by the hospital. 
A total of 1472 patients received IV PPI during this pe-
riod, out of which 75% charts were randomly selected for re-
view. A sequence randomizer (http://www.random.org) was 
used to generate a randomized sequence of patients. Patients 
who were already on PPI in out patient setting were excluded 
from the study. There was a high degree of confidence in the 
documentation of the indications for prophylaxis. All medi-
cal records are maintained in paper chart. All charts were 
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thoroughly reviewed including subspecialty consults to find 
indication for stress ulcer prophylaxis. 
The main outcome measure was the appropriateness of 
IV PPI use for stress ulcer prophylaxis, which was catego-
rized as indicated, possibly indicated or not indicated: (1) 
Any PPI use for stress ulcer prophylaxis as per American 
association of gastroenterology guidelines was defined as 
‘indicated’.  If  two  indications  were  documented,  the  one 
that  was  most  severe  or  required  the  longest  duration  of 
therapy was used; (2) If there was no documented indica-
tion for Stress ulcer prophylaxis, but a careful review of the 
chart suggested the presence of an approved indication as 
per AGA criteria, PPI use was categorized as ‘possibly indi-
cated’. For example, if there was no physician-documented 
indication for SUP but the patient was taking an NSAID or 
an anticoagulant with previous history of peptic ulcer dis-
ease, PPI use was categorized as ‘possibly indicated’; (3) 
The remaining cases with no documented indication for use 
were categorized as ‘not indicated’.
Additional data abstracted from the medical charts in-
cluded sociodemographic characteristics (age, sex and race), 
prior history of peptic ulcer disease, esophagogastroduode-
noscopy or NSAIDS/steroids use, admitting diagnosis, du-
ration of PPI use for SUP, and clinical outcome ( in terms 
of discharge or expired). Data analysis was performed using 
systat version 12. Associations between appropriate PPI use 
for stress ulcer prophylaxis and the sociodemographic and 
clinical characteristics of interest were assessed using Pear-
son’s X2 test.
As per guidelines from American Gastroenterology As-
sociation, following indications were considered to be ac-
ceptable for use of PPI as stress ulcer prophylaxis [3]: 
(1) Coagulopathy (platelet count < 50,000 mm3, INR > 
1.5, or aPTT > 2 times control); 
(2) Mechanical ventilation for more than 48 hours; 
(3)  History  of  gastrointestinal  ulceration  or  bleeding 
within 1 year before admission; 
(4) Have at least 2 of the following risk factors: Sepsis, 
ICU stays longer than 1 week, occult bleeding lasting 6 days 
or longer, and use of more than 250 mg hydrocortisone or 
the equivalent. 
These recommendations do not apply to patients with 
single-system injuries such as head trauma, spinal cord in-
jury, or thermal injury; patients with these injuries were ex-
cluded from studies in which subjects were randomized to 
receive prophylaxis or no prophylaxis.
Results
A total of 1472 patients received IV PPI during this period. 
And 1104 (75%) charts were randomly selected for review. 
 
Characteristics
 
Prophylaxis  
(n = 713)                                     
 
Treatment  
(n = 391)
 
Age, years
Mean 59                                                                   56 (7.7)
Range 18 - 99                                                                 18 - 94
Sex, no. (%)
Female 374 (52.4%)                                                      191 (48.8%)
Male 339 (48.6%)                                 200 (51.2%)
Race, no. (%)                                                                                                                                                
Black 576 (80%)           316 (80.8%)
Hispanic 38 (5.3%) 19 (4.8%)
White 56 (7.3%) 29 (7.4%)
Asian 21 (2.9%) 11 (2.8)
Others 22 (3.0%) 16 (4.0%)
Duration of PPI use
Mean 6.5 days                                                               2.3 days
Range 1 - 57 days                                                          1 - 11 days
Table 1. Patients Characteristics
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Based on chart reviews, patients who received IV PPI for 
therapeutic  indication  were  excluded. Approximately  713 
patients (64.5%) received IV PPI for stress ulcer prophy-
laxis. There were no significant differences in sociodemo-
graphic characteristics between included and excluded pa-
tients (Table 1).
Indicated Possibly-indicated Non-indicated
 
Floor
 
132 (22.4%)
 
55 (9.3%)
 
402 (68.4%)
 
589
ICU/telemetry 23 (18.5%) 10 (8.0%) 91 (73.3%) 124
Total 155 (22.1%) 65 (9.2%) 493 (68.5%) 713
Mean Age 60.6 58.4 58
Sex
Male 77 (48.7%) 30 (45.5%) 230 (46.6%)
Female 81 (51.2%) 36 (54.5%) 263 (53.3%)
Race
Black 126 (79.7%) 54 (81.8%) 406 (82.8%)
White 10 (6.3%) 4 (6.0%) 27 (5.3%)
Hispanic 13 (8.2%) 7 (10.6%) 41 (8.1%)
Asian 5 (3.1%) 1 (1.5%) 14 (2.6%)
Medics
NSAIDS 14 (8.8%) 10 (15.1%) 22 (4.2%)
Steroids 7 (4.4%) 5 (7.5%) 10 (1.8%)
Warfarin 2 (1.2%) 2 (3%) 3 (0.6%)
Days on PPI 7.2 5.4 5
Residents 20.9% 7.4% 69.8%
Attending Physicians 21.8% 9.8% 67.4%
Clinical Outcome
Discharged 144 (91.1%) 63.3 (95.4%) 478(97.3%)
Expired 8 (5.06%) 3 (4.5%) 13 (2.4%)
PPI on discharge 38 (26.3%) 18 (28.5%) 78 (15.8%)
Table 3. Data of PPI Indication 
 
Patient Disposition
 
ICU
 
124
 
17.3%
Floor 589 82.6%
Table 2. Patients Disposition
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In total, 17.3% of these patients were either admitted di-
rectly to ICU or were transferred to critical care during their 
hospital course (Table 2).
Careful data analysis showed that in 68.5% of cases IV 
PPIs were used without a proper indication (Table 3).  
One may infer that ICU setting and female sex itself is 
a risk factor for inappropriate use - ICU/telemetry: relative 
risk of 1.2 (95% CI of 0.84 to 1.04); Female sex: relative risk 
of 1.15 (95% CI 0.87 - 1.5).
There was no difference in inappropriate use between 
different racial groups. Prior history of NSAID use was sig-
nificantly higher in possibly indicated group. There was no 
significant difference in inappropriate use between residents 
and attending Physicians.  
In all these groups patients were discharged with PPI 
prescription, which in most cases did not have a proper in-
dication. We were not able to discern the exact number of 
patients discharged on inappropriate PPI prescription as the 
discharge summary section did not have column for indica-
tion.
A few of the common diagnosis where IV PPIs were 
given  for  stress  ulcer  prophylaxis  without  indication  are 
shown in Table 4.
The cost is as following: 
(1) Average number of days on IV PPI = 4.5; 
(2) Acquisition costs of PPIs vary among institutions as 
a result of purchasing contracts, and cost was estimated on 
the basis of price provided by the pharmacy of the hospital 
[4]; 
(3) Price of IV PPI (40 mg vial) = 7.5 USD; 
(4) Total number of non indicated PPI injections = 2445;   
(5) Estimated cost of medication = 18337 USD. 
This estimate is only for IV PPI in an inpatient setting in 
an inner city community hospital. It does not include price 
estimation of PO PPI and cost of health care staff.  If we 
can replicate these calculations on state or nation wide basis 
and do implicate the impact of documented side effects like 
ventilator associated pneumonia, price tag will certainly be 
significantly high.
Discussion
  
Proton pump inhibitors are very effective agents for stress 
ulcer prophylaxis. Recent literature has attributed a grow-
ing number of side effects to these drugs [5]. Most widely 
accepted are an increased incidence of ventilator associated 
pneumonia , clostridium difficile infection, increased risk of 
fall in elderly, and many potential drug interactions [4, 6]. A 
more rationale and judicious use will not only prevent un-
necessary health care expenditure but will definitely have a 
positive outcome on patient safety. 
This has been a persistent practice because of physicians’ 
perception of the safety of this medication, lack of knowl-
edge about practice parameters or a component of defensive 
medicine. Improving prescribing awareness through educa-
tion and a more active involvement of clinical pharmacist 
could reduce inappropriate use. Our data strongly suggest 
the need for institutional protocols and educational interven-
tions to promote evidence-based practice during residency 
training [7, 8]. Frequent review of therapy and improved 
communications between primary and secondary care are 
vital to rationalize the use of PPIs and to reduce expenditure 
[5].
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